Published on 26 Apr 2022 on Zacks via Yahoo Finance
We expect investors to focus on the sales performance of Assertio Holdings’ ASRT marketed drugs when it reports first-quarter 2022 results on May 9, after the market closes.
ASRT’s earnings surpassed expectations in two of the trailing four quarters and missed the same on the other two occasions, the average surprise being 20.8%. In the last reported quarter, Assertio Holdings witnessed a negative earnings surprise of 16.7%.
Assertio Holdings, Inc. Price and EPS Surprise